

LIST OF FIGURES

| | |
|---|----|
| Figure 1-1 Classification of transfection vectors..... | 5 |
| Figure 2-1 Lung cancer types and histology | 17 |
| Figure 2-2 Lung carcinogenesis(4) | 22 |
| Figure 2-3 Cellular factors responsible for drug resistance..... | 25 |
| Figure 2-4 Physiological factors responsible for drug resistance | 25 |
| Figure 2-5 Simplified schematic diagram on the basis of gene therapy (23) ... | 29 |
| Figure 2-6 Gene silencing mechanism through RNA interference technology (RNAi) | 30 |
| Figure 2-7 Major advantages offered by combined chemotherapy and siRNA therapy..... | 36 |
| Figure 2-8 Types of Dry Powder Inhalers..... | 37 |
| Figure 3-1 Calibration Plot of Cisplatin derivatized with OPDA (in DMF: Water Mixture 7:3 v/v, pH 6.2)..... | 57 |
| Fig. 3-2 Calibration plot of Cisplatin by NP-HPLC..... | 59 |
| Figure 3-3 Overlay Chromatogram of Cisplatin by NP-HPLC | 59 |
| Figure 3-4 Calibration plot of Cisplatin in Rat plasma by NP-HPLC | 62 |
| Figure 3-5 Overlay Chromatogram of Cisplatin in Rat plasma by NP-HPLC | 62 |
| Figure 3-6 Calibration plot of Cisplatin in Lung homogenate by NP-HPLC..... | 63 |
| Figure 3-7 Calibration plot of total phospholipids mixture in chloroform | 64 |
| Figure 3-8 Calibration plot of total phospholipids mixture in chloroform | 64 |
| Figure 3-9 Correlation of known concentration of siRNA (pmol/ μ l) Vs. obtained concentration (ng/ μ l) by Nanodrop results | 65 |
| Figure 3-10 Gel electrophoresis band density at different siRNA concentration | 67 |
| Figure 3-11 Calibration curve for prepared siRNA concentration and relative band density..... | 68 |
| Figure 4-1 Nanodrop spectra siRNA purity and concentration determination | 74 |

| | |
|---|-----------|
| Figure 4-2 siRNA stock solution stability | 75 |
| Figure 4-3 Gel electrophoresis of siRNA | 75 |
| Figure 4-4 Effect of temperature and pH on siRNA | 75 |
| Figure 4-5 DSC thermogram-I | 77 |
| Figure 4-6 DSC thermogram-II | 78 |
| Figure 4-7 IR spectrum of cisplatin | 79 |
| Figure 4-8 IR spectrum of physical mixture of HNCs components with cisplatin | 80 |
| Figure 4-9 IR spectrum of Sodium caprylate | 80 |
| Figure 4-10 IR spectrum of physical mixture of HNCs components..... | 81 |
| Figure 4-11 IR spectrum of cisplatin caprylate | 81 |
| Figure 5-1 Schematic diagram of architecture of HNCs..... | 99 |
| (Figure 5-2 Intensity based Nanocarrier size distribution: batch F1 to F15) . | 100 |
| Figure 5-3 Model diagnostic plots for Nanocarrier size | 108 |
| Figure 5-4 Box-cox plot for power transformation..... | 109 |
| Figure 5-5 Residuals vs factor plots | 110 |
| Figure 5-6 Pipel's plot on response variable 1..... | 111 |
| Figure 5-7 Response surface (3D) showing combined effect of Lipid concentration and polymer concentration on Nanocarrier size | 112 |
| Figure 5-8 Response surface (3D) showing combined effect of Lipid concentration and Lipid molar ratio on Nanocarrier size..... | 113 |
| Figure 5-9 Response surface (3D) showing combined effect of Polymer concentration and Lipid molar ratio on Nanocarrier size..... | 114 |
| Figure 5-10 Model diagnostic plots for Entrapment efficiency..... | 117 |
| Figure 5-11 Box-cox plot for power transformation of variable 2..... | 118 |
| Figure 5-12 Residuals vs factor plots of variable 2 | 119 |
| Figure 5-13 Pipel's plot on response of variable 2 | 120 |
| Figure 5-14 Response surface (3D) showing combined effect of Lipid concentration and polymer concentration on %Entrapment efficiency..... | 121 |
| Figure 5-15 Response surface (3D) showing combined effect of Lipid concentration and Lipid molar ratio on %Entrapment efficiency | 122 |

| | |
|--|-----|
| Figure 5-16 Response surface (3D) showing combined effect of Polymer concentration and Lipid molar ratio on %Entrapment efficiency | 123 |
| Figure 5-17 Desirability Plot..... | 124 |
| Figure 5-18 Intensity based Nanocarrier size distribution of optimized batch Batch R1 | 125 |
| Figure 5-19 Zeta potential distribution of Batch optimized batch R1 | 126 |
| Figure 5-20 Overlay Plot for Design space..... | 126 |
| Figure 5-21 Analysis of Design Space..... | 127 |
| Figure 5-22 HNCs SEM negative staining..... | 130 |
| Figure 5-23 HNCs SEM image negative staining Error! Bookmark not defined. | |
| Figure 5-24 Cryo-TEM of liposomes (Batch V3)..... | 130 |
| Figure 5-25Cryo-TEM of HNCs R1 | 131 |
| Figure 5-26 SEM image of HNCs R1 | 131 |
| Figure 5-27 cisplatin release from HNCs..... | 132 |
| Figure 5-28 Drug release kinetic: Higuchi model..... | 132 |
| Figure 5-29 Drug release kinetic models | 133 |
| Figure 5-30 HS-GC graph for standard chloroform..... | 133 |
| Figure 5-31 HS-GC graph for Residual solvent (Chloroform) present in HNCs formulation | 134 |
| Figure 5-32SAXS distance distribution profile | 135 |
| Figure 5-33 SAXS inter atomic vector distribution profile..... | 135 |
| Figure 5-34SAXS 3D modelling..... | 135 |
| Figure 6-1 Formation of siRNA anchored cisplatin caprylate loaded HNCs .. | 141 |
| Figure 6-2 Gel retardation assay siRNA-HNCs at different N/P ratio | 146 |
| Figure 6-3 Nanocarrier Size of developed HNCs after siRNA complexation . | 147 |
| Figure 6-4Zeta potential of developed HNCs after siRNA complexation | 148 |
| Figure 6-5HNCs Cryo TEM..... | 148 |
| Figure 6-6HNCs cryo TEM | 149 |
| Figure 6-7freeze fracture TEM..... | 149 |
| Figure 6-8 HNCs serum stability in absence of PEGylation layer..... | 150 |
| Figure 6-9 HNCs serum stability (with PEGylation layer)..... | 150 |

| | |
|---|-----|
| Figure 6-10 Naked siRNA serum stability..... | 150 |
| Figure 6-11 in vitro release of siRNA from HNCs..... | 151 |
| Figure 6-12 AFM HNCs-1 PEGylation layer thickness | 152 |
| Figure 6-13 AFM HNCs-2..... | 152 |
| Figure 7-1 MTT Dye Reduction by Mitochondrial Reductase Enzyme of Viable Cells..... | 158 |
| Figure 7-2 Haemocytometer diagram indicating the 16 corners squares which should be used for counting | 160 |
| Figure 7-3 Cytotoxicity siRNA-HNCs | 176 |
| Figure 7-4 Confocal images for qualitative cellular uptake study | 177 |
| Figure 7-5 FACS histogram..... | 178 |
| Figure 7-6 quantitative cellular uptake by FACS..... | 178 |
| Figure 7-7 Effect of folate on cellular uptake efficiency..... | 179 |
| Figure 7-8 MTT assay for cisplatin loaded siRNA-HNCs..... | 180 |
| Figure 7-9 MTT assay for cisplatin loaded HNCs..... | 180 |
| Figure 7-10 MTT assay for cisplatin solution | 181 |
| Figure 7-11 Wound scratch assay results | 183 |
| Figure 7-12 Dot plot histogram apoptosis detection FACS 1 | 184 |
| Figure 7-13 cell cycle analysis S+G2-M | 184 |
| Figure 7-14 Cell cycle analysis G0-G1 in negative control, positive control, R2- HNCs (L) and R2 siRNA-HNCs (R)..... | 185 |
| Figure 7-15 Gene expression study | 186 |
| Figure 8-1 Thermal Cycle for Freeze Drying..... | 192 |
| Figure 8-2 Flow of dry powder in the space of cascade impactor..... | 194 |
| Figure 8-3 Freeze drying cycle | 197 |
| Figure 8-4 lyophilized powder vials | 198 |
| Figure 8-5 Report of Malvern Mastersizer after powder after size reduction | 201 |
| Figure 8-6 <i>In-vitro</i> pulmonary deposition pattern of dry powder formulations using Respiritose SV003 | 203 |
| Figure 8-7 SEM image of the optimized blend for DPI formulation HNCs R4 | 204 |

| | |
|---|-----|
| Figure 8-8PXR image of Cisplatin..... | 204 |
| Figure8-9 PXR image of developed DPI after powder processing..... | 205 |
| Figure8-10 IR spectra of Cisplatin caprylate loaded DPI..... | 206 |
| Figure 8-11 IR spectra of Cisplatin caprylate | 206 |
| Figure 8-12 integrity of siRNA after DPI formation | 207 |
| Figure9-1 Cisplatin concentration in Broncho alveolar lavage (BAL) | 216 |
| Figure9-2 Cisplatin concentration in Lung homogenate at different time interval | 216 |
| Figure 9-3 In-vivo study for Marketed formulation and HNCs | 217 |
| Figure 9-4enzyme activity and L/B ratio | 219 |
| Figure 9-5 histopathological images | 220 |
| Figure 9-6Haemolysis by UV spectroscopy..... | 222 |
| Figure9-7 Hemolytic aggregation study..... | 222 |
| Figure9-8 Haemolysis by Optical method..... | 223 |